Ellen Hollywood

2.5k total citations
33 papers, 1.7k citations indexed

About

Ellen Hollywood is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ellen Hollywood has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Ellen Hollywood's work include Colorectal Cancer Treatments and Studies (13 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Cancer Treatment and Pharmacology (7 papers). Ellen Hollywood is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Cancer Treatment and Pharmacology (7 papers). Ellen Hollywood collaborates with scholars based in United States, Israel and Canada. Ellen Hollywood's co-authors include Leonard B. Saltz, Mithat Gönen, Heinz‐Josef Lenz, Axel-Rainer Hanauske, Kyle D. Holen, Diane Reidy‐Lagunes, Scott Wadler, Howard S. Höchster, Nancy E. Kemeny and Hedy L. Kindler and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Ellen Hollywood

33 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen Hollywood United States 17 1.3k 462 419 377 296 33 1.7k
Marine Gilabert France 22 910 0.7× 395 0.9× 422 1.0× 276 0.7× 399 1.3× 73 1.8k
Stephen Leong United States 23 1.1k 0.8× 842 1.8× 471 1.1× 350 0.9× 606 2.0× 73 2.3k
Kristen K. Ciombor United States 21 1.2k 0.9× 458 1.0× 383 0.9× 357 0.9× 307 1.0× 90 1.7k
D. J. Richel Netherlands 18 1.6k 1.2× 725 1.6× 894 2.1× 511 1.4× 513 1.7× 38 2.6k
Guillem Argilés Spain 24 1.8k 1.3× 719 1.6× 602 1.4× 321 0.9× 422 1.4× 95 2.5k
Francesco Sclafani United Kingdom 24 1.2k 0.9× 344 0.7× 440 1.1× 593 1.6× 323 1.1× 121 1.9k
Tiziana Pressiani Italy 19 735 0.5× 353 0.8× 440 1.1× 296 0.8× 348 1.2× 76 1.5k
Daisuke Kotani Japan 19 1.5k 1.1× 273 0.6× 729 1.7× 476 1.3× 376 1.3× 112 2.0k
R. Schulick United States 5 1.6k 1.2× 838 1.8× 343 0.8× 536 1.4× 658 2.2× 6 2.2k
Alessio Amatu Italy 24 1.5k 1.1× 598 1.3× 826 2.0× 419 1.1× 620 2.1× 80 2.4k

Countries citing papers authored by Ellen Hollywood

Since Specialization
Citations

This map shows the geographic impact of Ellen Hollywood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Hollywood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Hollywood more than expected).

Fields of papers citing papers by Ellen Hollywood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Hollywood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Hollywood. The network helps show where Ellen Hollywood may publish in the future.

Co-authorship network of co-authors of Ellen Hollywood

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Hollywood. A scholar is included among the top collaborators of Ellen Hollywood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Hollywood. Ellen Hollywood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harding, James J., Richard Kinh Gian, Imane El Dika, et al.. (2018). A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. Cancer Chemotherapy and Pharmacology. 82(3). 429–440. 32 indexed citations
2.
Lowery, Maeve A., Joanne F. Chou, Marinela Capanu, et al.. (2018). Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clinical Cancer Research. 25(3). 937–945. 25 indexed citations
3.
Lowery, Maeve A., David P. Kelsen, Marinela Capanu, et al.. (2017). Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer. 89. 19–26. 123 indexed citations
4.
Lowery, Maeve A., Eileen M. O’Reilly, James J. Harding, et al.. (2017). A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).. Journal of Clinical Oncology. 35(4_suppl). 290–290. 4 indexed citations
5.
Abou‐Alfa, Ghassan K., Jean‐Frédéric Blanc, Steven A. Miles, et al.. (2017). Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. The Oncologist. 22(7). 780–e65. 20 indexed citations
6.
O’Reilly, Eileen M., Maeve A. Lowery, Michal Segal, et al.. (2014). Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. Journal of Clinical Oncology. 32(15_suppl). 4023–4023. 30 indexed citations
7.
8.
Reidy‐Lagunes, Diane, Efsevia Vakiani, Michal Segal, et al.. (2012). A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors. Cancer. 118(19). 4795–4800. 56 indexed citations
9.
10.
Segal, Neil H., Diane Reidy‐Lagunes, Marinela Capanu, et al.. (2009). Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study). Journal of Clinical Oncology. 27(15_suppl). 4087–4087. 9 indexed citations
11.
Saltz, Leonard B., Heinz‐Josef Lenz, Hedy L. Kindler, et al.. (2007). Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study. Journal of Clinical Oncology. 25(29). 4557–4561. 332 indexed citations
12.
Holen, Kyle D., et al.. (2007). The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Investigational New Drugs. 26(1). 45–51. 214 indexed citations
13.
Azuma, Mizutomo, Dongliang Yang, Ellen Hollywood, et al.. (2007). Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2). Journal of Clinical Oncology. 25(18_suppl). 4113–4113. 2 indexed citations
14.
Chung, Ki Y., et al.. (2007). Bevacizumab 5mg/kg can be safely infused over 10 minutes. Journal of Clinical Oncology. 25(18_suppl). 4135–4135. 3 indexed citations
15.
Yang, Dongliang, Marinela Capanu, Ellen Hollywood, et al.. (2007). Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Journal of Clinical Oncology. 25(18_suppl). 4128–4128. 7 indexed citations
16.
Saltz, Leonard B., et al.. (2006). Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times?. Journal of Clinical Oncology. 24(18_suppl). 3542–3542. 6 indexed citations
17.
18.
Hollywood, Ellen. (2002). Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Seminars in Oncology Nursing. 18(2 Suppl 2). 30–35. 10 indexed citations
19.
Hollywood, Ellen, et al.. (2001). Nursing strategies for patients on oral chemotherapy.. PubMed. 15(1 Suppl 2). 37–9; discussion 40. 20 indexed citations
20.
Sharma, Sunil, Nancy E. Kemeny, Gary K. Schwartz, et al.. (2001). Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.. PubMed. 7(12). 3963–70. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marine Gilabert Breakdown of academic impact, for papers by Stephen Leong Breakdown of academic impact, for papers by Kristen K. Ciombor Breakdown of academic impact, for papers by D. J. Richel Breakdown of academic impact, for papers by Guillem Argilés Breakdown of academic impact, for papers by Francesco Sclafani Breakdown of academic impact, for papers by Tiziana Pressiani Breakdown of academic impact, for papers by Daisuke Kotani Breakdown of academic impact, for papers by R. Schulick Breakdown of academic impact, for papers by Alessio Amatu
Rankless by CCL
2026